Descriptions:
| Term | description type | Language/acceptability | Language/acceptability | Case significance |
|---|---|---|---|---|
| Product containing only [substance] (medicinal product) | FSN | us:P | gb:P | ci |
| [substance] only product | SYN | us:P | gb:P | ci |
Concept model:
| Attribute cardinality | Attribute | Value | role group number | role group cardinality |
|---|---|---|---|---|
| 1..1 | 0 | N/A | ||
| 1..1 | 0 | 1..1 | ||
| 1..1 |
766952006 |Count of base of active ingredient (attribute)|
| 0 | 1..1 |
Definition status:
Applies to:
< 763158003 |Medicinal product (product)|
Rules for description generation:
- Remove the semantic tag, (substance)
- Substances are the 'source of truth' so an alternate Preferred Term (PT) must always be added for all concepts when there are dialect variations in spellings for US/GB (language acceptability P/A) and vice versa
- Align case sensitivity with substance term for FSN (ci or cI) and PT (ci, CS or cI)
For content in the International Release, Has active ingredient (attribute)| should represent the base ingredient, not a modification, unless explicitly identified as an exception.
- Exceptions:
- Liposome substances (e.g. 426490000 |Vincristine liposome (substance)|)
- Lipid complex substances (e.g. 425953004 |Amphotericin B lipid complex (substance)|)
- Phospholipid complex substances (e.g. 768664009 |Amphotericin B phospholipid complex (substance)|)
- Cholesteryl complex substances (e.g. 427544000 |Amphotericin B cholesteryl sulfate complex (substance)|)
- Calcium lactate gluconate
- Exceptions:
JIRA ticket for implementation:
DRUGS-540 - Getting issue details... STATUS